We have recently demonstrated that DNA coding for both subunits of the murine IL -12 heterodimer exhibits a strong antimetastatic effect against B16 -melanoma in C57BL / 6 mice and after intratumoral injection tumor regression. Here we show that the antimetastatic effect can be detected when the DNA is injected intramuscularly 30 days before tumor cell challenge. A long -term IL -12 expression was measured for up to 50 days in the serum with a peak at day 20 amounting to about 10 ng / mL in C57BL / 6 mice. CpG oligodeoxynucleotides also induce IL -12 expression, however, only for a few hours. IL -12 DNA administration induces longlasting systemic IFN -production, whereas IL -4 and TNF -levels remained undetectable. NK cell ± depleted mice showed a strong but reduced expression of murine IL -12. Expression of DNA encoding human instead of murine IL -12 resulted in a significantly lower and transient expression, indicating that not plasmid -derived IL -12 production alone but the immune system of the host contributes to the long -lasting antimetastatic effect. It may be attributable to an autocrine feedback mechanism maintaining murine IL -12 expression, whereby several cell populations including NK cells are involved. Cancer Gene Therapy ( 2000 ) 7, 1557 ± 1565
D
NA plasmid vectors expressing an antigen under the control of a strong promoter have been shown to induce protective immunity to a number of pathogens, including viruses, bacteria, and parasites. 1 ± 5 Moreover, DNA therapy represents a new approach for autoimmune 6 and allergic diseases 7 and it has also shown efficacy in the treatment of cancer. 8 The immune response can be modulated by genetic adjuvants in the form of vectors expressing biologically active determinants, comprising cytokines (IL -2, IL -4, IL -5, IL -10, IL-12, IL-15, IL -18, IFN -, TNF -, GM -CSF, TGF -) , costimulators (B7.1, B7.2) , and ligands ( CD40L ) (reviewed in Ref. 2 ). In particular IL -12 ± encoding DNA induced cytotoxic T lymphocyte responses when combined with DNA coding for human immunodeficiency virus ( HIV ) or influenza antigens 9, 10 and displayed high antitumor and antimetastatic efficacy in several animal models. 11 ± 15 Bioactive IL -12, a disulfide-linked heterodimeric cytokine comprising p35 and p40 polypeptide chains, is mainly produced by dendritic cells, macrophages, and neutrophils. 16 This cytokine exerts its antitumor potential by three main mechanisms: ( 1) the increase of tumor immunogenicity via up -regulation of HLA class I, HLA class II, and ICAM -I expression; 17 ( 2) the inhibition of angiogenesis via an IFN±dependent mechanism; 18 and (3 ) the stimulation of cellmediated immunity. 19 ± 21 Cell -mediated immunity is promoted by ( 1) the direction of the immune system to the Th1 -type response, comprising the differentiation of CD4 + cells toward IFN --, TNF --, and IL -2 producing Th1 -type cells; 22 (2 ) the stimulation of macrophage function; 23 ( 3) the enhancement of specific cytotoxic T lymphocyte responses; 24 ( 4) the activation of natural killer (NK ) 19 and NK1 T cells; 25 and ( 5) the production of complement binding and opsonizing IgG2a, IgG2b, and IgG3 antibodies. 26 For cancer immunotherapy recombinant IL-12 protein has been applied intravenously ( i.v. ) or subcutaneously in phase I and phase II clinical trials showing antitumor efficiency against advanced malignant melanoma and renal cell carcinoma. 27 ± 30 Limitations of this therapy were the short half -life of this protein 31, 32 combined with high peaks of IL -12 serum concentrations generating serious toxicity. Side effects included fever, chills, fatigue, nausea, headache, anemia, neutropenia, lymphopenia, thrombocytopenia, hypoalbuminemia, hyperglycemia, triglyceridemia, liver function test abnormalities, and oral stomatitis. 27, 29, 33 Furthermore, treatment -related deaths associated with respiratory failure and hemorrhagic colitis were observed in a phase II clinical trial. 28 To improve safety and efficiency of protein therapies, several attempts have been made to increase the half -life of proteins. 34 Treatment with IL -12± encoding DNA, however, displays a high antitumor and antimetastatic potential and ensures a long -lasting IL-12 expression without high -peak serum concentrations or induction of serious side effects. 11,13 ± 15 With respect to the intended clinical use of IL-12 DNA, this investigation was aimed at elucidating the mechanisms of the immune response initiated by IL-12 DNA therapy. Immunological effects induced by genetic vaccination have been carefully studied, showing that the bulk of the immune response is generated by the expression of antigenic peptides encoded by plasmid DNA in nonlymphoid tissues, which are then transferred to and presented by bone marrow -derived antigen presenting cells (APC ). 35, 36 Little insight exists, however, in the subsequent immunological interactions induced by IL -12 gene therapy, which may explain its potent antitumor or antimetastatic effects.
METHODS

Plasmid DNA
The plasmid pIRES-muIL -12 contains the cDNA of murine IL -12 under the control of the CMV immediate early enhancer /promoter region. 14 The two subunits of IL -12, p35, and p40 are linked by an internal ribosomal entry site ( IRES ) of encephalomyocarditis virus. 37 Expression of both subunits after plasmid DNA injection was verified and quantified in cell culture supernatants of transiently transfected 293T cells using commercially available ELISA kits ( Genzyme, Cambridge, MA; Biosource International, Camarillo, CA ). For the construction of pIRES -huIL -12 the human IL-12 cDNA 38 was subcloned from pBLKS.IR-ES.hp35.hp40 by inserting the blunted XhoI/NotI fragment from pBLKS.IRES.hp35.hp40 into the EcoRV restriction site of pIRES. Expression of both subunits of human IL -12 was verified and quantified in cell culture supernatants of transiently transfected 293T cells using commercially available ELISA kits (Quantikine, R&D Systems, MN ) .
Large-scale preparation of plasmid DNAwas performed by the alkaline lysis method using Gigaprep columns and endotoxin -free reagents according to the supplier's protocol ( Qiagen, Hilden, Germany ). DNA was dissolved in phosphate -buffered saline ( PBS ) at a concentration of 1 g/L and administered intramuscularly ( i.m. ) by multiple injections (a total of four) into both quadriceps muscles of metofane anesthetized animals ( Metofane 40 were injected either intraperitoneally (i.p. ) or i.m.
Mice and tumors
C57BL /6, BALB / c, 129 wild -type (129SVev ), and IFNreceptor ±deficient mice 41 were bred in the animal facilities of the Institute of Medical Virology and used at 6 ±8 weeks of age. For tumor cell challenge the metastatic murine melanoma cell line B16F10, a gift from M. Burger, Basel, was used. 42 Cells were grown in Dulbecco's modified Eagle's media, supplemented with 10% fetal calf serum, 100 mg /mL streptomycin, 100 international units / mL penicillin, and 1 mmol / mL L -glutamine. Exponentially growing cells were harvested by trypsinization, washed twice in PBS and 1Â10 5 viable cells, as determined by Trypan blue dye exclusion, were injected i.v. into the tail vein in a total volume of 200 L. The number and size of metastases was examined after sacrificing the animals by visional inspection of the lungs according to Wexler. 43 
Antibodies
For depletion of NK cells the lyophilized polyclonal antiasialo GM1 rabbit antibody 44 was dissolved in 1 mL PBS according to the instructions of the manufacturer ( Wako, Osaka, Japan ) . This antibody solution ( 30 L ) was diluted to 500 L and injected i.p. 24 hours before DNA inoculation.
ELISAs
Blood samples were obtained by tail vein phlebotomy at indicated intervals post DNA injection. Serum IL -12 levels were measured using total IL-12 ELISA detecting both subunits of murine IL-12 (Genzyme; R&D systems ) at a 5 B16F10 melanoma cells. Pulmonary metastases were evaluated 20 days after tumor cell challenge. The number of animals per study group ranged from three to nine ( control n = 9; day 8 n = 5; day 13 n = 4; day 19 n = 4; day 25 n = 4; day 30 n = 4; day 60 n = 3 ) .
Cancer Gene Therapy, Vol 7, No 12, 2000 detection limit of 10 /20 pg /mL and IL -12 p70 mouse ELISA ( Genzyme ) measuring only the IL-12 heterodimer at a detection limit of 5 pg /mL. Interferon -( IFN -) (R&D systems; Biosource International ) , interleukin -4 ( R&D systems ) and TNF -levels ( Genzyme ) were determined by ELISA with detection limits of 2 /30, 14, and 30 pg/ mL, respectively. Human IL-12 was measured by ELISA detecting total human IL -12 (Quantikine, R&D systems ) with a sensitivity of 0.1 pg /mL. Assays were performed according to the protocols provided by the suppliers.
Statistical analysis
Statistical significance of differences between groups was determined by applying Student's t test or the Mann -Whitney test. P <0.05 was considered statistically significant.
RESULTS
Long -lasting antimetastatic effect of IL -12 DNA therapy
We previously reported on a pseudometastasis model using B16F10 cells, which colonize to the lung of C57BL /6 mice when injected i.v. Treatment with a eukaryotic expression vector containing the cDNAs coding for the two subunits of IL-12, p40, and p35, under the direction of the human cytomegalovirus ( CMV ) -immediate early ( IE -1 ) promoter /enhancer region as described earlier prevented metastases formation.
14 Injection of this vector leads to expression of the two subunits and measurable levels of the bioactive IL -12-heterodimer and IFN -in vivo. Here we investigated the surprising antimetastatic effect by pretreatment with DNA more systematically and assessed time course. C: Mean serum murine IL -12 levels in pIRES -muIL -12 plasmid DNA and empty plasmid injected C57BL / 6 mice shown with standard deviation. The difference in IL -12 serum levels were statistically significant ( P < .05, day 10, t test ) D: Levels of murine serum IL -12 concentration in BALB / c mice after i.m. injection of 100 g pIRES -muIL -12 plasmid DNA ( n = 5 ) or 100 g pIRES plasmid DNA as control ( n = 2; crossed rhomb and crossed circle ) . Serum concentration of murine IL -12 is well under 1 ng / mL in pIRES -muIL -12 ± injected mice and not significantly elevated ( P > .05 ) .
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To analyze the duration of the antimetastatic effect of IL -12 DNA therapy, mice were inoculated once with 100 g of pIRES -mu -IL -12 or pIRES as control at several time points before tumor cell challenge.
14 As shown in Table 1 , a single injection of IL -12 DNA significantly reduces metastasis formation for up to 30 days (P < .001 for 8, 13, 19, 25 and P < .05 for 30 days, respectively ).
Long -lasting IL -12 expression after i.m. injection of IL -12 ± encoding plasmid DNA To gain further insights in the immunological mechanisms underlying the antimetastatic effect of IL -12 DNA, an analysis of the time course of IL -12 serum levels after i.m. IL -12 DNA injection was performed (Fig 1 ) . Figure 1A and B, depicts curves of individual mice. Figure 1C shows the corresponding mean values. As can be seen, injection of plasmid DNA encoding IL -12 induces a long -lasting IL -12 production. IL -12 serum concentrations rise steadily for up to 20 days post DNA injection and remain elevated for up to 30 days. Mean serum IL -12 concentration on day 20 amounts to about 10 ng/ mL. Moreover, IL -12 serum levels differed between individual mice. One mouse exhibited a peak IL -12 serum concentration of 35 ng/ mL (Fig 1A ) , which is excluded from the graph in Figure 1B . The other mice showed much lower peak concentrations ranging from 1 to 4.5 ng IL -12 /mL. The long -lasting IL -12 production was mouse strain ± dependent and much weaker in BALB / c mice ( Fig 1D ) .
Long -lasting IL -12 and IFN -expression is not mediated by CpG motifs
It has recently been pointed out that immunostimulatory sequences (ISS ) harboring CpG motifs in the vicinity of palindromic sequences are present on prokaryotic DNA. 45 These have been described to induce proinflammatory cytokines. 40 To control for their contribution to the above described long -term IL -12 induction and to assess whether a short burst of IL-12 production induced by CpGODN was sufficient for long -lasting cytokine induction, oligodeoxynucleotides ( ODNs ) were injected i.p. and i.m. in C57BL /6 mice. A time -course analysis of IL -12 serum levels was performed. As shown in Figure 2A and B, CpG oligodeoxynucleotide ( CpGODN ) application leads to a short -term pronounced rise in IL-12 production. Mean peak concentrations of 38 15 and 64 37 ng /mL are detectable 4 hours after i.m. and i.p. DNA injection, respectively. IL -12 production declines rapidly to baseline levels within 2 days after ODN injection. GpGODN used as a control (Fig 2B ) did not induce detectable murine IL-12 serum levels. Significant murine IL -12 production was neither induced by administration of the vector pIREShuIL -12, which contains equal numbers of CpG motifs and pharmakokinetic properties very similar to pIRES-muIL -12 (data not shown ). Furthermore, in contrast to murine IL -12 DNA administration, i.m. application of CpGODN ( Fig 3B ) and the vector pIRES-huIL -12 (data not shown ) did not stimulate significant, long -lasting IFN -production. These results indicate that (1 ) a short -term pronounced rise in IL -12 production induced by CpGODN is not sufficient for the stimulation of long -term endogenous IL -12 and IFN -production. However, for endogenous cytokine stimulation low levels of ectopic IL -12 expression over a period of days are required. In addition, ( 2) plasmid -derived ISS do not mediate long -term cytokine production induced by murine IL-12 DNA delivery, because application of human IL -12 DNA did not lead to stimulation of endogenous sources.
Short -term expression of human IL -12 after i.m. injection of human IL-12 ± encoding plasmid DNA To better understand the long -term expression of murine IL-12 after a single DNA injection, we tried to distinguish direct IL -12 expression originating from the plasmid and triggered expression of endogenous IL-12 in the animals. For this purpose, human IL -12 encoding DNA was injected analogously to murine IL -12 DNA. Human IL -12 synthesis in mice exclusively originates from the injected plasmid and is therefore a measure for plasmid -derived gene expression. As shown in Figure 3A , IL -12 expression after human IL -12 ±encoding plasmid DNA injection is weak and shortlasting. This result implies that upon murine IL -12 DNA delivery into mice IL -12 expression originating from the plasmid most likely represents only a minor fraction and that the bulk of total IL -12 production is generated by stimulation of endogenous sources.
Additionally, to ensure that human IL-12 DNA delivery does not initiate endogenous murine IL-12 and IFNproduction, bioactivity of human IL -12 DNA was tested in mice in vivo. Therefore, IFN -and murine IL -12 serum levels were determined 0, 6, 24, 60, 120, 216, 288 and 0, 6, 24, 60, 120, 216 hours after injection of 100 g pIRES -huIL -12, respectively. Serum levels remained below the detection limits of 30 pg IFN -/mL and 20 pg muIL -12 /mL ( data not shown ), indicating that human IL -12 does not interact with the cytokine network of the mouse in vivo.
Differences in human and murine IL -12 serum levels may rely on differences in protein expression rates from the respective plasmids and not on the exclusive stimulation of endogenous cytokine production by murine IL -12 DNA. To exclude this possibility, protein expression rates were determined upon transfection of 293T cells with murine IL -12 (1 g pIRES -muIL12 ) and human IL -12 (1 g pIRES -huIL12) encoding plasmids. The resulting protein expression rates were of similar magnitude ( 7.3 ng murine IL -12/ 10 6 293T cells /12 hours and 9 ng human IL -12 /10 6 293T cells /12 hours ), indicating that differences in human and murine IL -12 serum levels do not stem from differences in protein expression rates but from the exclusive stimulation of endogenous sources by murine IL -12 DNA. mice were inoculated once with 100 g pIRES -huIL -12 DNA ( n = 3, white box ) and 100 g pIRES DNA as control ( n = 1, white rhomb ) , respectively. Human IL -12 serum levels were determined by ELISA. B: Time course of IFN -serum concentrations in C57BL / 6 mice i.v. challenged with 10 5 B16F10 melanoma cells on day 0. Mice were injected twice i.m. with 100 g pIRESmuIL -12 plasmid DNA ( n = 3; white box ) , 10 nmol CpG oligonucleotides ( n = 2; white circle ) , and 100 g pIRES plasmid DNA as control ( n = 1; black rhomb ) on day 0 and day 8, respectively. IFN -serum levels were significantly elevated in IL -12 DNA ± treated mice compared to CpG -treated and control mice ( P < .05, Mann -Whitney test ) . The second injection of pIRESmuIL -12 resulted in a significant boost in IFN -production ( P < .05, MannWhitney test, comparison days 16 / 4 ) . C: Kinetics of serum IFN -in BALB / c mice receiving a single i.m. injection of 100 g pIRES -muIL -12 ( n = 2; black box ) and as control 100 g pIRES ( n = 2; gray triangle ) on day 0. IFNserum levels were determined by ELISA at the indicated intervals post DNA injection. Each value represents the mean SD. IFN -serum levels were significantly different 96 hours post DNA injection ( P < .05, t test ) .
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IL-12 DNA induces long -term IFN -production
To further characterize the processes initiated by IL -12 DNA application, expression rates of the IL -12± inducible cytokines IFN -, TNF -, and IL -4 were determined. 19, 46, 47 These cytokines are characteristic of the functional diversity of CD4 + cells. IFN -and TNF -are produced by Th1 cells, whereas IL -4 is secreted by Th2 cells. 48 Results of IFN -expression are shown in Figure 3B and C. After i.m. application of 100 g IL -12 DNA on days 0 and 8 in C57BL /6 mice IFN -production peaks at day 15 with a mean serum concentration of 0.8 0.4 ng /mL. Interestingly, the second injection of IL -12 DNA results in a pronounced, significant boost of IFN -production ( Fig 3B ) (P < .05, Mann -Whitney test ), which is further enhanced by i.v. tumor cell challenge performed on day 0 with 10 5 B16F10 melanoma cells, as described by Brunda. 49 Induction of IL -4 and TNF -secretion above baseline levels was not detectable in C57BL /6 mice (data not shown ). In contrast to the amplification of IL -12 production, the induction of IFN -by IL -12 DNA was not mouse strain ± dependent. As shown in Figure 3C , BALB /c mice, which received a single injection of 100 g IL-12 DNA by the i.m. route, exhibited significantly elevated serum IFN -levels of 104 20 pg/ mL, which peaked 3 days post DNA injection, and then gradually decreased over a 30 -day interval ( P <.05, 96 hours post DNA injection, t test ) .
Regulation of IL -12 expression in IFN -receptor ± deficient mice
The results suggested that the induction of IFN -may play a role in the induction of a positive feedback loop observed after injection of murine IL -12 ± encoding DNA. This hypothesis was tested using IFN -receptor± deficient mice, in which IFN -cannot show its effector function. 41 These mice are on a 129 background (129SVev) and express high levels of IFN -upon injection of recombinant IL -12 protein ( in the range of 1000 ng IFN -/mL) 50 and IL-12 DNA (in the range of 460 pg IFN -/mL, unpublished results ) in contrast to their respective controls 129SVev mice ( in the range of 20 ng IFN -/mL upon IL -12 protein ( 50) and 40 pg IFN -/mL upon IL -12 DNA injection, unpublished results ) . IFN -receptor ± deficient mice and 129 SVev mice were i.m. injected once with murine IL-12 encoding plasmid DNA ( pIRES -muIL -12, 100 g) or control vector (pIRES, 100 g ). Serum probes were taken every 10 days. IL-12 serum levels were very low and not significantly elevated in both strains of mouse ( P >.05, t test ) (data not shown) .
NK cell depletion only partially abrogates the long -lasting IL -12 expression
To further characterize the cell population responsible for the induction of IL -12 by IFN -production, IL -12 serum levels were measured in NK cell± depleted C57BL /6 mice using polyclonal anti -asialo GM1 rabbit antibodies. As shown in Figure 4 , NK cell ± depleted mice showed a significant elevation of IL -12 serum levels with a maximum 10 days after IL-12 DNA inoculation (P < .05, t test ) . However, IL-12 serum levels were significantly lower in NK cell ± depleted mice compared to nondepleted mice (P < .05, 20 days post DNA injection, Mann -Whitney test ). The mouse with the highest peak concentration amounted to 2 ng /mL and the mean serum level on day 20 was 0.41 0.37 ng /mL. This supports the notion that IFN -producing NK cells contribute to the secondary induction of IL -12 by dendritic cells but do not represent the only cell population producing IFN -.
DISCUSSION
IL -12 DNA represents an important advance in immunotherapy to provide long -term antimetastatic efficiency. In a recent study using the B16F10/ C57BL / 6 modelsystem, pulmonary metastasis formation was prevented by i.m. IL -12 DNA administration 9 days before tumor challenge. In this model the antimetastatic effect was primarily mediated by NK cells and not by antiangiogenic effects.
14 Plasmid -derived ISS did not contribute to the antimetastatic effect, because delivery of both CpGODN Figure 4 . Time course of murine IL -12 serum concentrations in NK cell ± depleted compared to nondepleted C57BL / 6 mice. NK cell ± depleted mice ( n = 4 ) were treated with polyclonal anti -asialo GM1 rabbit antibody 24 hours before i.m. DNA application. Mice were injected once with 100 g pIRES -mu -IL12 ( NK cell ± depleted mice, n = 4, circles; nondepleted mice, n = 5, squares ) or 100 g pIRES ( control group, n = 2, rhombs ) on day 0. IL -12 serum levels were measured by ELISA at the indicated intervals post DNA injection. Each value represents the mean SEM. IL -12 serum levels were significantly lower in NK cell ± depleted mice compared to nondepleted mice ( P < .05, 20 days post DNA injection, Mann -Whitney test ) .
and a plasmid containing the IL -12 in the reversed orientation did not reduce metastasis formation. The present study extends this observation demonstrating that the high antimetastatic potential is observable 30 days after i.m. injection of IL -12 ±encoding DNA. This long -term antimetastatic effect of IL-12 DNA therapy raises hope for its clinical use in adjuvant and palliative cancer and metastasis immunotherapy. It is in contrast to the shortlived recombinant IL -12 protein with a half -life of about 3.5 hours in mice (mu -IL12 ) 31 and between 5 and 10 hours in humans (hu -IL -12) . 32 The antimetastatic efficiency of IL-12 DNA therapy is linked to a pattern of long -term IL -12 expression with respect to duration and variability. Peak IL-12 concentrations are reached 20 days after i.m. DNA injection. Up to this time -point IL -12 DNA ± treated mice were either free of metastases or exhibited only isolated pulmonary colonies. Variations of IL -12 expression in individual mice, which ranged from 1000 to 7000 pg IL -12 /mL on day 10, may be correlated to variations in biological antimetastatic effects induced after IL-12 DNA administration and thus may explain the phenomenon that in some mice metastasis formation is not entirely prevented.
IL-12, synthesized mainly by activated mononuclear phagocytes and dendritic cells, is a potent and required inducer of efficient IFN -production by T cells as well as NK cells. 19, 51 Correspondingly, in the present study high IFN -levels were observed after IL -12 DNA application. Although the amount of IL-12 produced after IL-12 DNA administration differed considerably between C57BL / 6 mice and BALB /c mice, the induction of biological activity as measured by IFN -was not mouse strain ± dependent. Moreover, IFN -production was boosted after the second IL -12 DNA injection. Interestingly, in accordance to IL -12 synthesis, the rise of IFN -production showed a protracted rise reaching peak serum levels several days after the second IL -12 DNA administration, which may be explained by the ability of IL-12 to mediate both acute induction of the IFN -gene subsiding within 12 hours in vivo 31 and stable priming for high production of IFN -. Furthermore, this delayed response, which was also observed after application of recombinant IL-12 protein, 52 may be attributed in part to the lack of appropriate costimulatory signals (TNF -, IL-1, B7, CD58 ) provided to some extent by APCs. 53 ± 55 IL-12 acts as a differentiation factor on CD4 + ( Th0 ) cells, promoting their specialization into Th1 cells 22 by priming T cells for IFN -production and by enhancing the ability of differentiated Th1 clones to produce IFN -. 56 Mainly due to indirect effects on APCs 57 Th2 development and characteristic cytokine production of the Th2 -type, comprising IL -4, IL -5, IL -6, and IL-13, is suppressed by IL-12. 58, 59 Correspondingly, i.m. IL -12 DNA administration directed the immune response to the Th1 -type inducing the production of large amounts of the Th1 -type cytokine IFN -and suppressing synthesis of the Th2 -type cytokine IL -4. With respect to the mouse strain dependence of IL -12 serum levels after IL -12 DNA administration it is interesting to note that the genetic background of mice determines the balance between IL-4, IFN -, and IL -12, 60 and thereby CD4 + development. In contrast to T cells from B10.D2 mice, T cells from BALB /c mice rapidly lose expression of IL -12R2 chain in neutral conditions ( in cultures without the addition of exogenous cytokines ), 61 which represents one of the major mechanisms by which IL -4 down -regulates IL-12 signaling. 62 BALB /c mice favor Th2 -type immune responses, 63, 64 which may explain the lack of the secondary induction of IL -12 expression by APCs in this mouse strain.
Recently, it has been shown that the antimetastatic potential of IL -12 DNA therapy is independent of the induction of IFN -synthesis. This was the case for a shortterm antimetastatic effect.
14 For a long -term effect IL-12 DNA ±induced IFN -production, however, may be of primary importance, because it has been shown that IFNprofoundly enhances the ability of monocytes and polymorphonuclear neutrophil leukocytes to produce IL-12. 65 In the present study we demonstrate that IFN -production is important for long -lasting endogenous IL -12 expression. Intramuscular production of IL -12 protein upon i.m. injection of IL -12 DNA may initiate a feedback loop, IL -12 can then act on T cells and NK cells to produce IFN -, which in turn can stimulate the synthesis of endogenous IL -12 by APCs.
To support this hypothesis three experimental interruptions of the suggested feedback loop were performed. We have shown that (1 ) human IL -12, which is not bioactive in mice in vivo, does not initiate the cytokine circle. Furthermore, ( 2) NK cells play a role, because a positive cytokine feedback loop was maintained in NK cell ± depleted mice even though the IL -12 serum levels were reduced compared to nondepleted mice. The cytokine network is hence sufficiently established by IFN -production originating from Th1 cells. Nevertheless, NK cells, which predominantly contribute to the early production of IFN -in response to IL -12, 66 are necessary for its full activation. In addition, (3 ) the feedback loop is interrupted in IFN -receptor± deficient mice as evidenced by IL -12 serum levels below 1 ng /mL despite profound IFN -production upon IL-12 DNA injection. However, elevated IL -12 serum levels were neither detectable in the control group, SVev mice. This finding may rely on the fact that inducibility of IFNproduction, which represents an essential part of the feedback loop, was weak in this strain of mouse and much less compared to IFN -receptor ±deficient mice. These results may support the hypothesis that in IFNreceptor ±deficient mice APCs cannot be activated by IFN -to produce IL-12. Finally, (4 ) The results propose that IL -12 expressed from plasmid DNA initiates the positive feedback system, thereby directing the immune response to the Th1 development. The early triggering of the cellular immune response appears to be important for the antimetastatic efficiency of IL -12 DNA treatment. Regulation of the induced immune reaction is performed by the immune system itself. Thus, physiological secondary effects appear to be responsible for effective tumor defense induced by IL -12 ± encoding DNA. These physiological secondary events seem to be well controlled by the immune system itself, because no significant toxic effects have been observed after i.m. IL -12 DNA application up to now. 14 
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